EMERGENT BIOSOLUTIONS INC. Net Income (Loss) Attributable to Parent, Diluted
EMERGENT BIOSOLUTIONS INC. (EBS) reported Net Income (Loss) Attributable to Parent, Diluted of $4.20 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-01.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-05-01
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent, diluted for the quarter ending 2026-03-31 was $4.20M.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-03-31 was $0.00.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month |
|---|---|
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-01 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |